ben
leflunomid
initi
develop
agricultur
herbicid
explor
immunosuppress
abil
inhibit
enzym
dihydroorot
dehydrogenas
potenti
leflunomid
immunosuppress
field
transplant
extens
demonstr
variou
experiment
studi
long
halflif
sever
day
pose
problem
potenti
overimmunosuppress
transplant
patient
analog
activ
metabolit
leflunomid
develop
call
malononitrilamid
mna
also
known
best
studi
synthet
mna
much
shorter
halflif
leflunomid
hour
vs
day
believ
repres
attract
altern
leflunomid
applic
organ
transplant
leflunomid
n
prodrug
rapidli
convert
biolog
activ
metabolit
teriflunomid
serum
level
teriflunomid
refer
leflunomid
level
halflif
teriflunomid
long
human
approxim
day
drug
enter
enterohepat
recircul
excret
intestin
urinari
system
equal
proport
leflunomid
insolubl
water
suspend
carboxymethylcellulos
oral
administr
chemic
mna
design
structur
similar
oral
bioavail
substanti
affect
food
gender
effect
pharmacokinet
observ
phase
studi
leflunomid
analog
strong
antiprolif
effect
lymphocyt
b
lymphocyt
thu
limit
format
antibodi
inhibit
pyrimidin
synthesi
import
mechan
action
leflunomid
directli
inhibit
enzym
dihydroorot
dehydrogenas
lymphocyt
reli
entir
de
novo
pathway
pyrimidin
biosynthesi
use
anoth
socal
pyrimidin
salvag
pathway
dihydroorot
dehydrogenas
inhibit
lead
deplet
nucleotid
precursor
uridin
triphosph
cytidin
triphosph
necessari
synthesi
rna
dna
henc
strongli
suppress
dna
rna
synthesi
vivo
mechan
action
leflunomid
may
depend
factor
drug
level
dispos
uridin
pool
immun
activ
pathway
involv
studi
indic
addit
inhibit
dihydroorot
dehydrogenas
leflunomid
mna
may
act
inhibit
tyrosin
kinas
phosphoryl
epiderm
growth
factor
receptor
human
fibroblast
shown
inhibit
leflunomid
shown
leflunomid
directli
inhibit
interleukin
il
protein
tyrosin
kinas
activ
associ
activ
cell
complex
higher
concentr
also
inhibit
tyrosin
phosphoryl
janu
kinas
jak
protein
tyrosin
kinas
leflunomid
analog
also
shown
possess
strong
inhibitori
activ
antiapoptot
tyrosin
kinas
bruton
tyrosin
kinas
key
factor
cellindepend
antibodi
format
hypothesi
leflunomid
may
exhibit
one
mechan
action
vivo
illustr
mice
uridin
restor
prolifer
igm
product
lipopolysaccharidestimul
b
cell
wherea
suppress
igg
product
revers
phenomenon
correl
dosedepend
manner
tyrosin
phosphoryl
protein
known
involv
signal
transduct
pathway
doubl
vivo
mechan
action
confirm
rat
xenoreact
counteract
administr
uridin
wherea
alloreact
inhibit
variou
macrophag
function
leflunomid
mna
also
describ
particular
inhibit
product
oxygen
radic
inhibit
igemedi
hypersensit
respons
express
receptor
type
well
tumor
necrosi
factor
tnf
mediat
nuclear
factor
kappa
b
activ
tacrolimu
also
inhibit
matur
dendrit
cell
prevent
upregul
activ
marker
product
phenomenon
revers
exogen
uridin
equival
stronger
immunosuppress
activ
leflunomid
vitro
vivo
immunosuppress
effect
synergist
calcineurin
inhibitor
cni
mycophenol
mofetil
mmf
interestingli
leflunomid
shown
possess
antivir
effect
although
precis
mechan
unclear
inhibit
viral
replic
member
herpesviru
famili
prevent
tegument
acquisit
viral
nucleocapsid
late
stage
virion
assembl
implic
leflunomid
effect
multidrugresist
cytomegaloviru
cmv
vitro
although
vitro
activ
modest
select
index
low
anticmv
effect
leflunomid
confirm
rat
model
heterotop
heart
transplant
anoth
interest
featur
leflunomid
vasculoprotect
effect
independ
inhibit
dihydroorot
dehydrogenas
variou
rodent
transplant
studi
leflunomid
shown
least
equal
potent
cyclosporin
abl
synerg
cyclosporin
induc
toler
specif
characterist
leflunomidemedi
immunosuppress
rat
abil
interrupt
ongo
acut
reject
efficaci
prevent
treat
chronic
vascular
reject
one
attract
characterist
leflunomid
mna
strong
capac
delay
xenograft
reject
induc
partial
xenograft
toler
may
relat
strong
suppress
effect
leflunomid
cellindepend
xenoantibodi
format
capac
induc
natur
killer
nk
cell
nonrespons
modul
xenoantigen
express
monotherapi
rat
combin
microemulsifi
cyclosporin
dog
tacrolimu
nonhuman
primat
reduc
chronic
allograft
nephropathi
significantli
prolong
renal
allograft
surviv
main
role
leflunomid
renal
transplant
nowaday
treatment
bk
viru
nephropathi
bkvn
although
efficaci
never
document
trial
base
vitro
effect
antibk
concentr
vivo
target
level
mgml
propos
prospect
studi
renal
transplant
recipi
biopsyproven
bkvn
treat
leflunomid
combin
discontinu
mmf
reduct
tacrolimu
ngml
rang
although
leflunomid
level
lower
rang
averag
mgml
signific
reduct
serum
urin
bk
viru
bkv
titer
obtain
allograft
function
stabil
overal
graft
loss
rate
bkv
less
encourag
result
obtain
anoth
prospect
openlabel
studi
viral
clearanc
obtain
patient
signific
toxic
result
discontinu
drug
patient
contribut
reduct
immunosuppress
agent
leflunomid
efficaci
bkvn
treatment
unclear
moment
base
recent
vitro
data
suggest
combin
mammalian
target
rapamycin
mtor
inhibit
leflunomid
might
effect
treatment
approach
treatment
leflunomid
kidney
transplant
recipi
bk
viremia
abl
prevent
develop
bkvn
studi
jaw
et
al
report
three
kidney
transplant
recipi
bkvn
treat
combin
leflunomid
everolimu
patient
experienc
signific
reduct
viral
load
one
complet
resolut
two
patient
preserv
allograft
function
end
followup
case
report
patient
resistantrefractori
cmv
infect
extens
cutan
wart
patient
kaposi
sarcoma
success
treat
leflunomid
also
studi
context
bkvn
although
abl
decreas
bk
viral
load
treatment
associ
acut
reject
decreas
renal
function
advers
event
compar
reduct
immunosuppress
anim
studi
leflunomid
abl
revers
acut
chronic
reject
two
clinic
studi
report
leflunomid
capabl
stabil
allograft
function
patient
worsen
allograft
function
due
chronic
allograft
dysfunct
phase
ii
multicent
studi
perform
involv
renal
transplant
patient
combin
tacrolimu
corticosteroid
patient
receiv
experienc
reduc
number
acut
reject
effect
graft
surviv
week
reduct
acut
reject
episod
pronounc
subgroup
target
level
obtain
second
week
note
mean
total
lowdens
lipoprotein
cholesterol
level
lower
group
versu
placebo
group
valid
result
hamper
design
studi
time
develop
field
organ
transplant
ceas
although
rat
toler
leflunomid
well
dog
readili
develop
anemia
gastrointestin
ulcer
reportedli
frequent
side
effect
arthriti
patient
receiv
longterm
leflunomid
treatment
diarrhea
nausea
alopecia
rash
lead
dropout
rate
recent
thrombot
microangiopathi
attribut
leflunomid
report
patient
treat
bkvn
phase
ii
studi
mention
previous
involv
dosedepend
increas
side
effect
includ
anemia
hypokalemia
symptomat
myocardi
ischemia
esophag
report
side
effect
pneumon
peripher
neuropathi
leflunomid
teratogen
effect
anim
human
washout
period
cholestyramin
advis
women
men
consid
concept
combin
leflunomid
methotrex
might
increas
risk
bone
marrow
suppress
liver
toxic
furthermor
rifampin
acceler
convers
leflunomid
teriflunomid
might
increas
level
combin
warfarin
potenti
increas
intern
normal
ratio
role
leflunomid
renal
transplant
limit
treatment
patient
bkvn
promis
result
report
respect
mna
shorter
halflif
consid
promis
class
immunosuppress
result
random
clinic
trial
disappoint
develop
agent
organ
transplant
halt
ethyl
hydrochlorid
synthet
structur
analog
myriocin
metabolit
ascomycet
isaria
sinclairii
type
veget
wasp
maxim
concentr
area
curv
proport
dose
indic
pharmacokinet
profil
linear
volum
distribut
larg
superior
blood
volum
indic
widespread
tissu
penetr
undergo
hepat
metabol
long
halflif
around
hour
newli
develop
select
agonist
astella
pharma
inc
uniqu
mechan
action
mainli
affect
lymphocyt
traffick
act
highaffin
agonist
sphingosin
bind
receptor
result
intern
render
lymphocyt
unabl
respond
natur
occur
gradient
low
concentr
thymu
secondari
lymphoid
organ
high
concentr
lymph
plasma
retain
lymphocyt
environ
lymphoid
organ
administr
mice
b
cell
immedi
leav
peripher
blood
migrat
peripher
lymph
node
mesenter
lymph
node
peyer
patch
cell
return
peripher
blood
withdraw
drug
without
undergo
apoptot
death
alter
cell
traffick
accompani
reduct
lymphocyt
infiltr
graft
organ
interestingli
lymphocyt
treat
ex
vivo
reintroduc
vivo
similarli
migrat
peripher
lymphoid
tissu
indic
act
directli
lymphocyt
process
acceler
home
complet
block
vivo
coadministr
monoclon
antibodi
vitro
presenc
increas
express
certain
intercellular
adhes
molecul
human
endotheli
cell
thu
alter
cell
traffick
may
result
direct
action
lymphocyt
also
effect
endotheli
cell
interestingli
suggest
regulatori
cell
differ
affect
compar
teffector
cell
regulatori
cell
express
lower
level
receptor
henc
show
reduc
respons
furthermor
vitro
tregulatori
cell
possess
increas
suppress
activ
antigenspecif
prolifer
assay
unlik
cni
poor
inhibitor
cell
function
vitro
particular
influenc
antigeninduc
product
vitro
exposur
high
concentr
induc
chromatin
condens
typic
dna
fragment
format
apoptot
bodi
whether
administr
vivo
also
associ
signific
apoptosi
matter
debat
also
present
murin
dendrit
cell
upon
administr
dendrit
cell
lymph
node
spleen
reduc
express
downregul
transendotheli
migrat
diminish
recent
studi
demonstr
inhibit
lymphangiogenesi
thu
prolong
allogen
islet
surviv
mice
experiment
experi
given
daili
oral
gavag
mark
antireject
properti
mice
rat
dog
monkey
mgkg
prolong
surviv
corneal
skin
allograft
highli
allogen
rodent
model
da
lew
rat
combin
short
cours
peritranspl
oral
mgkg
day
prolong
cardiac
allograft
surviv
effici
posttranspl
treatment
tacrolimu
mgkg
cardiac
liver
allograft
surviv
prolong
august
copenhagen
irish
aci
rat
lew
rat
model
either
induct
mainten
treatment
even
delay
administr
interrupt
ongo
allograft
reject
suggest
role
rescu
agent
block
reject
also
graftversushost
diseas
rat
intestin
transplant
may
also
protect
ischemiareperfus
injuri
partial
cytoprotect
action
smalland
largeanim
model
provid
evid
act
synergi
cni
benefit
result
pharmacokinet
interact
induct
cours
act
synergi
posttranspl
tacrolimu
prolong
cardiac
allograft
surviv
rat
similar
phenomenon
observ
use
posttranspl
combin
cyclosporin
rat
skin
heart
allograft
show
synergist
effect
cni
heart
liver
transplant
aci
lew
rat
model
show
synergi
cyclosporin
dog
kidney
mgkgday
monkey
kidney
mgkgday
transplant
mgkg
synerg
cni
dog
liver
transplant
synergi
rapamycin
also
observ
rat
cardiac
transplant
murin
lung
transplant
model
attenu
ischemiareperfus
injuri
sensit
murin
cardiac
transplant
model
combin
result
inhibit
alloantibodi
product
reduct
donorspecif
cell
prolong
allograft
surviv
benzyloxyphenylthio
ethyl
hydrochlorid
similar
molecular
structur
alon
combin
lowdos
cyclosporin
mmf
prolong
skin
heart
renal
allograft
surviv
short
cours
balbc
mice
receiv
islet
allograft
result
significantli
prolong
islet
allograft
surviv
addit
inject
intragraft
regulatori
cell
allow
prolong
drugfre
graft
surviv
suggest
tolerogen
effect
rat
dose
mgkg
level
significantli
decreas
number
peripher
lymphocyt
addit
heart
transplant
studi
rat
indic
combin
suboptimaldos
tacrolimu
significantli
prolong
allograft
surviv
compar
combin
suboptimaldos
tacrolimu
wider
margin
safeti
term
side
effect
macular
edema
bradycardia
studi
use
cynomolgu
monkey
renal
transplant
model
evalu
combin
suboptimaldos
tacrolimu
anim
receiv
allograft
median
surviv
time
significantli
prolong
stabl
renal
transplant
patient
maintain
cyclosporin
toler
well
one
oral
dose
mg
similarli
effect
anim
singl
dose
caus
lymphopenia
dosedepend
intens
durat
equal
affect
cell
cell
memori
cell
cell
b
cell
phase
ii
iii
studi
de
novo
renal
transplant
shown
mg
combin
fulldos
cyclosporin
steroid
effect
mmf
combin
fulldos
cyclosporin
steroid
although
patient
lower
creatinin
clearanc
month
mg
allow
reduct
cyclosporin
exposur
mg
combin
reduceddos
cyclosporin
result
underimmunosuppress
also
combin
tacrolimu
mg
superior
mmf
recent
studi
de
novo
renal
transplant
recipi
recent
report
combin
everolimu
benefici
regard
prevent
acut
reject
preserv
allograft
function
renal
transplant
recipi
high
risk
delay
graft
function
side
effect
gener
similar
immunosuppress
hypertens
anemia
constip
nausea
commonli
report
side
effect
specif
bradycardia
macularretin
edema
dyspnea
transient
rise
liver
function
test
although
consid
main
impedi
clinic
develop
reduct
heart
rate
first
dose
transient
persist
mainten
phase
importantli
typic
side
effect
cni
nephrotox
neurotox
diabetogen
observ
uniqu
mechan
action
avail
clinic
studi
show
superior
standard
care
therefor
futur
organ
transplant
uncertain
bredinin
nucleosid
analog
structur
similar
ribavirin
first
isol
cultur
media
ascomycet
eupenicillium
brefeldianum
harvest
soil
hachijo
island
japan
weak
antibiot
activ
candida
albican
mizoribin
exert
immunosuppress
function
select
inhibit
enzym
inosin
monophosph
dehydrogenas
guanosin
monophosph
synthetas
requir
gener
guanosin
monophosph
inosin
monophosph
de
novo
pathway
contrast
azathioprin
mizoribin
incorpor
nucleic
acid
cell
result
fewer
side
effect
myelosuppress
hepatotox
mizoribin
found
inhibit
humor
cellular
immun
select
inhibit
lymphocyt
prolifer
canin
model
renal
transplant
mizoribin
prolong
graft
surviv
human
compar
azathioprin
mizoribin
show
equal
potent
immunosuppress
activ
fewer
advers
effect
expect
base
similar
structur
ribavirin
mizoribin
exhibit
vitro
antivir
activ
cmv
respiratori
syncyti
viru
measl
hepat
c
corona
viru
parainfluenza
influenza
viru
clinic
studi
mizoribin
substitut
mmf
patient
bkv
urin
bkv
dna
urin
becam
neg
five
seven
patient
remain
two
patient
signific
decreas
urinari
bkv
dna
acut
reject
deterior
graft
function
occur
studi
period
mycophenol
substitut
mizoribin
also
shown
abl
prevent
revers
gastrointestin
symptom
japanes
studi
suggest
differ
combin
includ
mizoribin
cyclosporin
basiliximabcorticosteroid
everolimustacrolimu
live
donor
kidney
transplant
toxic
princip
advers
reaction
associ
use
mizoribin
leukopenia
abnorm
hepat
function
rash
increas
level
uric
acid
vomit
hyperuricemia
result
acut
renal
failur
renal
transplant
recipi
treat
highdos
mizoribin
mizoribin
mainli
use
japan
infrequ
use
elsewher
consequ
experi
mizoribin
limit
result
show
safe
effect
immunosuppress
human
kidney
transplant
antivir
activ
mizoribin
might
yet
anoth
drug
evalu
set
bkvn
sever
inhibitor
develop
eg
tyrphostin
dimethoxyquinazolin
compound
tofacitinib
mannich
base
sever
shown
possess
immunosuppress
properti
given
lymphocyterestrict
role
inhibitor
consid
interest
novel
class
immunosuppress
drug
multipl
potenti
candid
compound
one
enter
clinic
trial
atp
congen
tofacitinib
pfizer
nj
bind
atp
catalyt
site
jak
molecul
propos
analysi
cellular
level
could
adequ
mean
monitor
immunomodulatori
effect
tofacitinib
oral
bioavail
tofacitinib
tofacitinib
volum
distribut
tofacitinib
metabol
primarili
much
lesser
extent
metabolit
larg
inact
due
metabol
pathway
drug
interact
solidorgan
transplant
recipi
expect
dose
adjust
necessari
presenc
azol
antifung
rifamycin
dose
adjust
recommend
context
renal
hepat
failur
tyrosin
kinas
essenti
signal
transduct
common
gammachain
cytokin
receptor
nucleu
express
receptor
restrict
immun
cell
make
attract
target
new
immunosuppress
signal
transduct
mediat
obligatori
lymphocyt
activ
differenti
homeostasi
evidenc
find
defici
result
sever
combin
defici
syndrom
possibl
detriment
effect
interfer
signal
relat
fact
toler
induct
essenti
depend
pathway
thu
challeng
immunosuppress
drug
design
achiev
select
inhibit
versu
activ
tofacitinib
initi
claim
select
inhibitor
found
less
activ
base
inhibitori
concentr
ic
valu
howev
numer
laboratori
publish
inconsist
ic
result
variou
jak
domain
tofacitinib
inhibit
greater
degre
initi
thought
also
inhibit
margin
tofacitinib
potent
inhibitori
potenc
nm
select
inhibitor
develop
date
rodent
nonhuman
primat
tofacitinib
exert
strong
suppress
immun
reaction
prolong
surviv
cardiac
renal
allograft
monotherapi
significantli
delay
onset
reject
kidney
allograft
nonhuman
primat
tofacitinib
significantli
reduc
product
express
cell
furthermor
tofacitinib
inhibit
cellular
alloimmun
respons
vitro
administr
vivo
result
reduct
nk
cell
cell
number
wherea
effector
memori
cell
level
unalt
recent
shown
tofacitinib
select
inhibit
cell
effector
function
preserv
suppress
activ
high
regulatori
cell
tofacitinib
evalu
induct
mainten
therapi
phase
iia
multicent
openlabel
random
control
trial
kidney
transplant
recipi
patient
receiv
induct
therapi
mmf
steroid
patient
group
receiv
tacrolimu
patient
group
administ
tofacitinib
mg
mg
twice
per
day
respect
high
incid
bkvn
tofacitinib
group
protocol
adjust
stop
mmf
decreas
steroid
exposur
compar
tacrolimu
tofacitinib
group
show
similar
rate
acut
reject
episod
allograft
function
experienc
greater
incid
hyperlipidemia
infect
suggest
addit
inhibit
phase
iib
trial
compar
cyclosporin
standard
dosag
versu
tofacitinib
mg
twice
per
day
month
mg
twice
per
day
tofacitinib
mg
twice
per
day
month
mg
twice
per
day
addit
patient
receiv
induct
therapi
mmf
steroid
unexpectedli
lower
tofacitinib
dosag
arm
show
trend
toward
lowest
reject
rate
superior
allograft
function
howev
studi
import
advers
event
includ
seriou
infect
posttranspl
lymphoprolif
diseas
tofacitinib
arm
post
hoc
analysi
studi
patient
reclassifi
base
median
tofacitinib
exposur
h
postdos
concentr
abovemedian
exposur
less
belowmedian
exposur
mgml
incid
biopsyproven
acut
reject
noninferior
compar
cyclosporin
group
howev
seriou
infect
cmv
diseas
significantli
increas
abovemedian
exposur
group
posttranspl
lymphoprolif
disord
ptld
case
occur
abovemedian
exposur
group
seriou
advers
event
due
leukopenia
neutropenia
remain
signific
tofacitinib
group
compar
cyclosporin
group
dose
escal
studi
frequent
advers
event
infect
gastrointestin
side
effect
tofacitinib
mg
mg
twice
per
day
associ
mean
decreas
hemoglobin
baselin
addit
decreas
nk
cell
b
cell
chang
number
neutrophil
total
lymphocyt
platelet
cell
cell
summari
combin
tofacitinib
mmf
result
accept
rate
acut
reject
evid
overimmunosuppress
tofacitinib
mg
twice
per
day
combin
mmf
tofacitinib
mg
twice
per
day
coadminist
mmf
result
similar
outcom
associ
modest
lipid
elev
higher
rate
viral
infect
opinion
consid
known
side
effect
profil
cni
evalu
tofacitinib
warrant
given
side
effect
report
use
tofacitinib
challeng
remain
develop
immunosuppress
drug
truli
select
inhibit
versu
activ
lack
success
develop
select
antagonist
probabl
relat
focu
chemic
analog
atp
wherea
success
expect
develop
molecul
display
alloster
inhibit
via
bind
noncatalyt
site
timeweight
h
postdos
concentr
therapeut
drug
monitor
tofacitinibtr
group
potenti
interest
relaunch
tofacitinib
immunosuppress
drug
kidney
transplant
recipi
especi
patient
refractori
acut
reject
blockad
prevent
immunolog
skew
toward
memori
cell
sotrastaurin
lowmolecularweight
synthet
compound
potent
revers
inhibit
isoform
protein
kinas
c
pkc
importantli
lesser
activ
sotrastaurin
primarili
metabol
hepat
inact
metabolit
ndesmethylsotrastaurin
similar
potenc
sotrastaurin
present
low
blood
concentr
less
parent
exposur
renal
excret
sotrastaurin
neglig
small
amount
excret
bile
dose
elimin
halflif
sotrastaurin
averag
hour
clinic
trial
recommend
patient
administ
sotrastaurin
consist
either
without
food
avoid
foodrel
fluctuat
drug
exposur
time
clinic
drug
interact
studi
date
demonstr
sotrastaurin
increas
area
concentrationtim
curv
everolimu
tacrolimu
sotrastaurin
increas
tacrolimu
concentr
inasmuch
tacrolimu
dose
need
achiev
given
c
lower
combin
sotrastaurin
versu
mmf
convers
sotrastaurin
area
concentrationtim
curv
increas
cyclosporin
ketoconazol
pkc
famili
serinethreoninespecif
protein
kinas
involv
divers
signal
transduct
pathway
modul
whole
rang
cellular
process
includ
activ
prolifer
differenti
apoptosi
autophagi
shown
essenti
cell
signal
transduct
pathway
modul
respons
includ
product
control
b
cell
receptorinduc
transactiv
tindepend
b
cell
respons
final
influenc
macrophag
function
note
sotrastaurin
demonstr
nontox
ad
human
islet
cultur
result
suggest
appropri
immunosuppress
candid
clinic
trial
islet
transplant
recent
shown
nonhuman
primat
sotrastaurin
combin
cyclosporin
subtherapeut
dose
result
markedli
prolong
renal
allograft
surviv
indic
synergist
immunosuppress
effect
phase
ii
random
control
trial
sotrastaurin
standard
reduc
tacrolimu
compar
standard
tacrolimu
alon
addit
induct
therapi
steroid
three
month
posttranspl
stabl
patient
sotrastaurin
switch
tacrolimu
mmf
three
arm
show
equal
efficaci
month
end
studi
differ
allograft
function
although
incid
acut
reject
significantli
higher
standard
tacrolimu
sotrastaurin
arm
lack
efficaci
studi
prematur
discontinu
anoth
recent
trial
de
novo
renal
transplant
recipi
immedi
graft
function
studi
subject
random
sotrastaurin
tacrolimu
patient
receiv
basiliximab
mmf
steroid
studi
demonstr
lower
degre
efficaci
better
renal
function
cnifre
regimen
sotrastaurin
mmf
versu
tacrolimusbas
control
combin
sotrastaurin
everolimu
evalu
twostag
phase
ii
studi
de
novo
kidney
transplant
recipi
evalu
sotrastaurin
phase
patient
random
sotrastaurin
mg
cyclosporin
csa
phase
ii
patient
random
sotrastaurin
mg
csa
patient
receiv
basiliximab
everolimu
evr
prednison
composit
efficaci
failur
rate
treat
biopsyproven
acut
reject
graft
loss
death
lost
followup
month
higher
sotrastaurin
arm
stage
sotrastaurin
mg
csa
stage
sotrastaurin
mg
mg
csa
egfr
significantli
better
sotrastaurin
group
versu
csa
time
point
except
month
anoth
random
control
trial
patient
random
receiv
sotrastaurin
mg
mg
twice
per
day
plu
standard
tacrolimu
stac
ngml
sotrastaurin
mg
n
twice
per
day
plu
reduc
tacrolimu
rtac
ngml
entericco
mycophenol
acid
mpa
plu
stac
patient
receiv
basiliximab
corticosteroid
sotrastaurin
mg
group
prematur
discontinu
higher
composit
efficaci
failur
treat
biopsyproven
acut
reject
grade
ia
graft
loss
death
loss
followup
versu
mpa
group
sotrastaurin
mg
compar
efficaci
mpa
prevent
reject
signific
differ
renal
function
group
clinic
trial
mention
previous
incid
tachycardia
incid
seriou
infect
dosedepend
chronotrop
effect
observ
preclin
phase
sotrastaurin
studi
therefor
higher
heart
rate
tachycardia
observ
sotrastaurin
combin
mmf
unexpect
tachycardia
advers
event
mild
major
occur
soon
transplant
studi
tedescosilva
et
al
gastrointestin
cardiac
advers
event
frequent
sotrastaurin
wherea
higher
treatment
discontinu
death
graft
loss
occur
sotrastaurin
mg
studi
russ
et
al
mean
heart
rate
gastrointestin
advers
event
discontinu
due
advers
event
frequent
sotrastaurin
wherea
leukopenia
frequent
mpa
sotrastaurin
block
pkcmediat
earli
cell
activ
provid
new
approach
immunosuppress
distinct
cni
howev
efficaci
result
phase
ii
studi
support
combin
sotrastaurin
mg
twice
per
day
mmf
cnifre
regimen
addit
sotrastaurin
evalu
nonren
transplant
recipi
data
suggest
nonnephrotox
bortezomib
proteasom
inhibitor
approv
food
drug
administr
treatment
multipl
myeloma
bortezomib
increasingli
use
set
solidorgan
transplant
bortezomib
administ
four
dose
mgm
intraven
infus
period
kidney
transplant
recipi
bortezomib
administr
patient
need
premed
methylprednisolon
peak
serum
concentr
reach
minut
drug
clear
within
hour
bortezomib
select
inhibitor
proteasom
prevent
activ
induc
apoptosi
rapidli
divid
metabol
activ
cell
extens
protein
synthesi
abil
bortezomib
target
plasma
cell
spur
interest
new
therapeut
approach
treatment
prevent
alloantibodi
format
organ
transplant
vitro
bortezomib
associ
reduct
number
bone
marrowderiv
plasma
cell
attenu
alloantibodi
product
bortezomib
primarili
act
plasma
cell
deplet
result
reduc
antibodi
product
tdepend
antigen
margin
zone
b
cell
resist
bortezomibmedi
effect
tindepend
type
respons
less
affect
mous
model
lupu
bortezomib
deplet
shortand
longliv
plasma
cell
result
reduct
antidoublestrand
dna
antibodi
product
vogelbach
et
al
recent
establish
bortezomib
alon
combin
sirolimu
also
prevent
alloantibodi
format
rat
model
kidney
transplant
sever
clinic
trial
report
ongo
evalu
bortezomib
prevent
treatment
acut
humor
reject
howev
mix
result
report
context
everli
et
al
administ
bortezomib
six
patient
antibodymedi
reject
concomit
acut
cellular
reject
refractori
current
avail
therapi
bortezomib
administr
result
resolut
antibodymedi
reject
six
patient
decreas
donorspecif
antibodi
level
improv
allograft
function
anoth
studi
walsh
et
al
report
result
bortezomib
treatment
patient
antibodymedi
reject
bortezomib
treatment
associ
variabl
result
better
respons
earli
occur
first
month
transplant
versu
late
occur
month
transplant
antibodymedi
reject
although
studi
report
bortezomibbas
desensit
induc
longterm
decreas
donorspecif
antibodi
studi
sberrosoussan
et
al
bortezomib
treatment
result
decreas
donorspecif
antibodi
mean
fluoresc
intens
use
sole
desensit
therapi
four
renal
transplant
recipi
subacut
antibodymedi
reject
persist
donorspecif
antibodi
densit
procotol
also
includ
iv
ig
rituximab
plasmapheresi
imposs
attribut
reduct
donorspecif
antibodi
sole
bortezomib
moreov
report
mayo
clinic
modest
reduct
hla
antibodi
titer
effect
cpra
flow
crossmatch
observ
recent
report
nonhuman
primat
undergo
fulli
mismatch
allogen
skin
transplant
report
bortezomib
treatment
follow
rebound
effect
character
increas
circul
igg
b
cell
increas
germin
center
b
cell
follicular
helper
cell
lymph
node
reaction
term
humor
compens
author
shown
driven
b
cell
activ
factor
tnf
famili
baff
data
suggest
futur
trial
combin
bortezomib
agent
inhibit
baff
signal
belimumab
atacicept
newer
proteasom
inhibitor
carfilzomib
result
irrevers
inhibit
wherea
bortezomib
induc
tempor
inhibit
proteasom
studi
ongo
evalu
carfilzomib
desensit
protocol
patient
preform
hla
antibodi
treatment
acut
humor
reject
lung
transplant
gener
bortezomib
administ
intraven
twice
weekli
month
mgm
per
administr
common
side
effect
associ
bortezomib
treatment
gastrointestin
toxic
includ
paralyt
ileu
thrombocytopenia
neuropathi
potenti
sever
disabl
date
increas
rate
opportunist
infect
report
importantli
although
bortezomib
associ
substanti
reduct
donorspecif
antibodi
level
result
decreas
protect
antibodi
level
proteasom
inhibitor
therapi
potenti
treatment
antibodymedi
reject
kidney
transplant
recipi
primari
rescu
therapi
optim
respons
bortezomib
obtain
antibodymedi
reject
occur
earli
posttranspl
bortezomib
treatment
initi
promptli
recent
data
suggest
bortezomib
combin
agent
inhibit
baff
signal
belimumab
atacicept
prevent
rebound
humor
immun
oh
new
synthet
structur
analog
consid
promis
immunomodul
addit
wellknown
role
miner
bone
homeostasi
nonclass
effect
vitamin
immun
regul
increasingli
recogn
role
oh
immun
regul
suggest
presenc
receptor
vitamin
receptor
vdr
almost
immun
cell
control
vdr
express
immun
cell
immun
signal
presenc
vitamin
metabol
enzym
b
lymphocyt
dendrit
cell
allow
local
convers
oh
oh
oh
result
immatur
tolerogen
phenotyp
dendrit
cell
induct
high
low
regulatori
cell
b
cell
apoptosi
clear
addit
even
synergist
effect
observ
oh
analog
classic
immunosuppress
cyclosporin
sirolimu
mmf
vitro
sever
vivo
autoimmun
diseas
model
autoimmun
diabet
experiment
autoimmun
encephalomyel
transplant
model
monotherapi
oh
analog
provok
modest
prolong
graft
function
human
data
still
lack
sustain
propos
benefit
vitamin
supplement
optim
immun
function
random
trial
involv
lung
transplant
recipi
monthli
oral
vitamin
supplement
cholecalciferol
iu
result
increas
level
vitamin
clinic
outcom
unaffect
chronic
lung
allograft
dysfunct
overal
surviv
preval
acut
reject
lymphocyt
bronchiol
infect
lung
function
pulmonari
system
inflamm
bone
miner
densiti
major
concern
remain
side
effect
oh
calcium
bone
metabol
apoptosi
play
import
immun
system
control
lymphocyt
delet
primari
secondari
lymphoid
organ
apoptosi
also
play
critic
role
mainten
immun
toler
two
pathway
apoptosi
intrins
extrins
apoptosi
pathway
describ
agent
specif
influenc
intrins
apoptosi
pathway
shown
promis
immunosuppress
agent
report
inhibit
allogen
immun
respons
combin
lymphopenia
delet
alloreact
cell
rel
enrich
regulatori
cell
vitro
inhibit
allogen
cell
activ
prolifer
cytotox
vivo
combin
lowdos
csa
result
longterm
skin
graft
surviv
murin
major
histocompat
complex
mhc
mismatch
model
furthermor
combin
lowdos
csa
costimul
blockad
induc
stabl
mix
chimer
toler
mhcmismatch
murin
bone
marrow
transplant
model
interestingli
also
induc
apoptosi
memori
cell
prolong
skin
allograft
surviv
sensit
mice
anoth
inhibitor
current
evalu
clinic
trial
concern
system
lupu
erythematosu
novel
inhibitor
mtor
pathway
report
mtor
kinas
subunit
mtor
complex
mtor
complex
although
rapamycin
partial
inhibit
mtor
complex
inhibit
mtor
complex
dual
blockad
mtor
complex
mtor
complex
shown
potenti
abrog
chronic
reject
rat
cardiac
allograft
model
atpcompetit
inhibitor
compet
atp
inhibit
mtor
complex
new
class
mtor
inhibitor
mainli
evalu
anticanc
properti
evalu
immunosuppress
power
inhibitor
cell
prolifer
vitro
cours
induc
prolong
heart
allograft
surviv
murin
mhcmismatch
heart
transplant
model
rapidli
metabol
human
hepatocyt
result
short
halflif
therefor
novel
compound
develop
longer
halflif
current
evalu
phase
ii
trial
oncolog
rapidli
absorb
oral
intak
median
time
peak
minut
elimin
halflif
approxim
hour
import
interpati
variabl
current
recommend
dose
mg
twice
daili
cladribin
adenosin
deaminaseresist
analog
deoxyadenosin
use
treatment
leukemia
lymphoma
number
studi
explor
immunosuppress
capac
cladribin
vitro
cladribin
inhibit
b
cell
prolifer
vivo
cladribin
monotherapi
shown
prolong
skin
allograft
surviv
mice
combin
cyclosporin
prolong
liver
heart
allograft
surviv
rat
effect
cyclosporin
monotherapi
smallbowel
allograft
howev
clinic
trial
publish
date
farnesyltransferas
inhibitor
develop
anticanc
compound
inhibit
ra
gtpase
inhibit
lectininduc
prolifer
antigenpres
cellinduc
cell
prolifer
compound
also
inhibit
lymphocyt
cytokin
product
promot
apoptosi
lectinactiv
lymphocyt
anoth
farnesyltransferas
inhibitor
shown
vitro
block
secret
cell
suppress
alloreact
rat
heterotop
cardiac
transplant
model
alon
combin
subtherapeut
dose
cyclosporin
delay
develop
acut
reject
given
combin
antireject
antioncogen
effect
farnesyltransferas
inhibitor
could
repres
attract
new
class
immunosuppress
malignancypron
organ
transplant
recipi
futur
clinic
trial
confirm
efficaci
cell
receptor
recogn
specif
antigen
lymphoid
cellspecif
kinas
lck
phosphoryl
togeth
receptorassoci
complex
phosphoryl
zincassoci
phosphorylas
event
trigger
downstream
cascad
increas
intracellular
calcium
activ
calcineurin
inhibitor
lck
becom
avail
recent
structur
similar
molecul
shown
prolong
surviv
heterotop
murin
heart
renal
subcapsular
islet
graft
well
blunt
product
immunoglobulin
emodin
c
h
cyclic
deriv
rhubarb
root
rhizom
shown
prolong
murin
skin
graft
surviv
dampen
product
howev
neither
archetyp
compound
show
suffici
specif
lck
versu
kinas
warrant
clinic
develop
fr
immunosuppress
agent
isol
cultur
pseudomona
fluorescen
inhibit
transcript
activ
act
predominantli
antigenpres
cell
fr
demonstr
synergi
tacrolimu
vitro
vivo
murin
model
skin
transplant
compar
optim
dose
tacrolimu
alon
combin
fr
tacrolimu
prolong
graft
surviv
brequinar
sodium
exert
immunosuppress
effect
inhibit
enzym
dihydroorot
dehydrogenas
result
inhibit
b
lymphocyt
although
characterist
brequinar
suggest
would
attract
immunosuppress
suboptim
pharmacolog
profil
jeopard
use
transplant
patient
futur
use
drug
field
transplant
requir
develop
analog
exhibit
shorter
halflif
reduc
toxic
spergualin
origin
isol
cultur
filtrat
bacillu
laterosporu
explor
new
anticanc
antibiot
substanc
analog
subsequ
becam
wide
known
promis
new
immunosuppress
precis
mode
action
larg
unknown
poor
oral
bioavail
must
deliv
parenter
hamper
widespread
clinic
use
efficaci
demonstr
treatment
kidney
allograft
reject
aboincompat
kidney
transplant
transplant
sensit
patient
analog
develop
allow
oral
administr
major
clinic
indic
limit
treatment
reject
crise
may
interest
altern
steroid
antilymphocyt
agent
fact
remain
effect
recurr
administr
promis
upon
cellular
uptak
cyclophosphamid
extens
metabol
activ
compound
phosphoramid
mustard
acrolein
reaction
phosphoramid
mustard
dna
result
cell
death
limit
efficaci
multipl
side
effect
standard
indic
cyclophosphamid
transplant
today
desensit
highli
sensit
recipi
kidney
transplant
protocol
involv
repeat
plasmapheresi
combin
cyclophosphamid
either
without
continu
steroid
kidney
transplant
becom
avail
sever
decad
total
lymphoid
irradi
tli
use
treatment
hodgkin
diseas
possibl
appli
tli
immunosuppress
regimen
rather
anticanc
treatment
discov
investig
stanford
univers
procedur
tli
deliv
two
port
first
socal
mantl
port
includ
lymph
node
neck
axilla
mediastinum
port
call
invert
encompass
aortic
iliac
pelvic
lymph
node
spleen
usual
total
dose
gy
gy
rad
administ
daili
fraction
gy
much
current
avail
experiment
evid
immunolog
mechan
underli
tliinduc
toler
point
import
suppressor
cell
group
stroberidentifi
posttli
suppressor
cell
hosttyp
nk
cell
protect
effect
tli
graftversushost
diseas
abrog
mice
gene
hosttyp
nk
cell
produc
stimul
donortyp
cell
produc
also
definit
evid
function
import
activ
suppressor
cell
deliv
demonstr
could
prevent
graftversushost
diseas
vivo
posttli
attenu
effector
tlymphocyt
reactiv
equal
propos
respons
observ
immunosuppress
state
tli
intrins
cell
defect
depend
irradi
thymu
extrathym
tissu
tli
anerg
cell
shown
incap
prolifer
even
presenc
exogen
studi
tli
shown
lead
thymic
clonal
delet
donoror
hostreact
lymphocyt
tlitreat
mice
also
exhibit
decreas
antidonor
cytotox
cell
precursor
frequenc
final
strober
group
show
lymphocyt
recov
soon
tli
wherea
lymphocyt
remain
defici
sever
month
show
defect
also
prevent
thymic
shield
irradi
domin
tli
confirm
group
rodent
larg
anim
recent
nador
et
al
demonstr
toler
induct
condit
tli
antithymocyt
globulin
atg
depend
abil
natur
occur
regulatori
nk
cell
regulatori
cell
suppress
residu
alloreact
cell
capabl
reject
allograft
tlitreat
balbc
mice
receiv
fulli
allogen
bone
marrow
skin
graft
first
day
tli
becam
stabl
hematopoiet
chimera
without
sign
graftversushost
diseas
develop
perman
donorspecif
toler
preserv
antithirdparti
reactiv
toler
induct
critic
depend
width
irradi
field
time
transplant
tli
total
dose
tli
absenc
presensit
although
bone
marrow
chimer
could
easili
induc
toler
either
heart
kidney
allograft
obtain
suggest
tliinduc
bone
marrow
chimer
necessarili
creat
toler
toward
organspecif
antigen
combin
tli
lowdos
cyclosporin
found
effect
clinic
safe
rat
tli
postop
atginduc
perman
specif
transplant
toler
toward
heart
allograft
transplant
dog
encourag
result
led
similar
trial
clinic
kidney
transplant
myburgh
et
al
appli
modifi
tli
regimen
baboon
low
dosag
widefield
exposur
show
toler
achiev
larger
anim
without
concomit
bone
marrow
transplant
also
heart
heartlung
transplant
experi
xenogen
nonhuman
primat
speci
preoper
tli
administ
combin
cyclosporin
atg
cyclosporin
splenectomi
cyclosporin
medrol
effici
treatment
regimen
pretranspl
tli
combin
cyclosporin
methotrex
pig
heartintobaboon
model
result
graft
surviv
time
week
regimen
abl
inhibit
xenoreact
natur
antibodi
product
xenoreact
macrophag
pig
isletintorat
xenograft
model
tli
combin
deoxyspergualin
extrem
effect
even
discord
lambintopig
model
tli
synerg
cyclosporin
azathioprin
provok
increas
mean
xenograft
surviv
time
princip
disadvantag
clinic
applic
tli
complet
regimen
fraction
daili
irradi
need
administ
complet
suffici
close
moment
transplant
find
suitabl
donor
organ
within
restrict
time
frame
problemat
investig
therefor
explor
possibl
use
tli
transplant
mous
rat
heart
allograft
model
posttranspl
tli
significantli
prolong
graft
surviv
combin
monoclon
antibodi
infus
donortyp
dendrit
cell
precursor
first
clinic
kidney
transplant
util
tli
perform
univers
minnesota
patient
previous
reject
renal
allograft
similar
result
increas
graft
surviv
compar
histor
control
data
achiev
patient
popul
use
cyclosporin
eas
administr
investig
conclud
prefer
cyclosporin
tli
control
trial
perform
univers
leuven
endstag
diabet
nephropathi
patient
receiv
cadaver
kidney
allograft
investig
effect
pretranspl
tli
daili
fraction
gy
follow
weekli
tli
dose
suitabl
donor
found
follow
lowdos
posttranspl
prednison
mainten
treatment
longterm
followup
reveal
reject
episod
frequent
patient
graft
surviv
significantli
inferior
tlitreat
group
excess
mortal
tlitreat
patient
due
sepsi
result
highdos
steroid
therapi
need
treat
reject
crise
clinic
experi
confirm
anim
data
also
show
tli
insuffici
provok
longterm
graft
surviv
toler
extra
manipul
need
studi
stanford
univers
patient
receiv
first
one
patient
second
cadaver
renal
allograft
use
tli
atg
actuari
graft
surviv
year
respect
ten
patient
never
reject
crisi
despit
overal
poor
hlamatch
donor
recipi
followup
studi
specif
antidonor
mix
lymphocyt
cultur
hypoor
nonrespons
demonstr
patient
immunosuppress
drug
could
withdrawn
evalu
larger
group
patient
treat
protocol
center
show
graft
surviv
less
cyclosporinetr
patient
around
posttranspl
tli
combin
monoclon
antibodi
atg
donorspecif
blood
transfus
seem
effect
rat
heart
allograft
model
basi
result
efficaci
tli
evalu
heart
transplant
patient
therapyresist
earli
vascular
reject
result
signific
reduct
reject
recurr
effect
maintain
least
year
meantim
favor
result
confirm
sever
group
also
tlitreat
patient
develop
less
coronari
atherosclerosi
match
control
despit
multipl
reject
episod
scandl
et
al
report
use
tli
induc
toler
set
combin
kidneyhematopoiet
stem
cell
transplant
hlamatch
donor
recipi
pair
patient
receiv
condit
regimen
dose
tli
cgi
five
dose
rabbit
atg
mmf
month
cyclosporin
least
month
donor
hematopoiet
stem
cell
inject
intraven
day
outpati
infus
center
recent
studi
scandl
et
al
report
patient
undergo
hla
match
mismatch
combin
kidneyhematopoiet
transplant
sixteen
match
patient
persist
chimer
least
month
success
withdrawn
immunosuppress
whether
immunosuppress
withdrawn
mismatch
patient
mix
chimer
remain
establish
time
conclus
tli
shown
safe
immunosuppress
regimen
abandon
clinic
practic
organiz
reason
except
treatment
therapyresist
reject
heart
heartlung
transplant
howev
abil
induc
toler
hlamatch
patient
combin
atg
hematopoiet
stem
cell
transplant
might
renew
interest
treatment
modal
date
evid
radiationrel
late
effect
document
tli
extracorpor
photopheresi
techniqu
leukocyt
remov
patient
leukopheresi
expos
ultraviolet
light
develop
immunoregulatori
treatment
erythroderm
cutan
cell
lymphoma
subsequ
procedur
shown
safe
altern
treatment
variou
human
immun
autoimmun
diseas
furthermor
rat
monkey
regimen
shown
result
extend
skin
allograft
cardiac
allograft
xenograft
surviv
differ
mechan
shown
contribut
immunomodulatori
effect
photopheresi
select
inhibit
effector
cell
induct
high
rate
apoptosi
increas
capac
phagocytos
apoptot
cell
result
induct
anticlonotyp
immun
respons
shift
toward
immun
activ
induct
regulatori
cell
clinic
transplant
photopheresi
appli
therapeut
prophylact
option
appli
treatment
recurr
resist
acut
reject
renal
transplant
patient
number
patient
includ
studi
limit
prospect
random
trial
need
safeti
efficaci
photopheresi
prevent
acut
reject
cardiac
allograft
evalu
primari
cardiac
allograft
recipi
randomli
assign
standard
tripledrug
immunosuppress
therapi
cyclosporin
azathioprin
prednison
alon
conjunct
photopheresi
session
perform
first
month
transplant
month
followup
photopheresistr
patient
develop
significantli
fewer
multipl
reject
signific
differ
rate
type
infect
although
signific
effect
graft
surviv
rate
month
studi
indic
photopheresi
may
effect
new
immunosuppress
regimen
transplant
recipi
patient
refractori
bronchiol
obliteran
lung
transplant
photopheresi
result
stabil
graft
function
andor
patient
histolog
revers
reject
splenectomi
pretranspl
splenectomi
recipi
transplant
first
propos
starzl
et
al
mean
improv
graft
surviv
although
splenectomi
standard
procedur
patient
develop
hypersplen
azathioprineassoci
leukopenia
evid
role
splenectomi
enhanc
graft
surviv
controversi
larg
prospect
random
trial
minneapoli
show
splenectomi
improv
graft
surviv
significantli
longerterm
followup
show
loss
benefici
effect
increas
infectionrel
mortal
sever
singlecent
studi
shown
alarm
risk
sepsi
death
nullifi
earli
benefit
splenectomi
graft
surviv
multicent
analysi
southeastern
organ
procur
foundat
confirm
modest
improv
graft
surviv
splenectomi
relentless
increas
patient
mortal
splenectomi
place
prepar
recipi
receiv
aboincompat
graft
practic
like
becom
wide
employ
live
relat
donor
transplant
aboincompat
otherwis
suitabl
donor
avail
donor
alexandr
et
al
report
seri
aboincompat
live
donor
transplant
recipi
prepar
plasmapheresi
donorspecif
platelet
transfus
splenectomi
although
author
believ
need
plasmapheresi
donorspecif
platelet
transfus
reevalu
splenectomi
thought
import
recipi
splenectomi
lost
graft
acut
vascular
reject
contrast
undergo
splenectomi
smallscal
success
experi
postsplenectomi
aboincompat
live
donor
kidney
transplant
also
report
ishikawa
et
al
japan
set
aboincompat
kidney
transplant
antigenspecif
immunoadsorpt
rituximab
bortezomib
treatment
develop
altern
plasmapheresi
splenectomi
reduc
indic
splenectomi
organ
transplant
splenectomi
also
appli
combin
eculizumab
salvag
therapi
patient
develop
sever
antibodymedi
reject
hlaincompat
kidney
transplant
followup
report
splenectomi
substitut
splenic
irradi
plasmapheresi
increasingli
use
facilit
kidney
transplant
patient
high
level
antihla
antibodi
abo
incompat
furthermor
plasmapheresi
use
treatment
antibodymedi
allograft
reject
plasmapheresi
compon
sever
desensit
protocol
appli
patient
live
donor
incompat
crossmatch
donorspecif
antibodi
differ
combin
plasmapheresi
rituximab
corticosteroid
iv
ig
bortezomib
report
plasmapheresi
perform
crossmatch
test
becom
neg
typic
daili
basi
altern
day
number
plasmapheresi
session
depend
antibodi
level
degre
mismatch
transplant
perform
within
day
last
desensit
rebound
antihla
antibodi
titer
occur
encourag
earli
result
approach
report
although
associ
consider
morbid
recent
studi
provid
evid
import
surviv
benefit
patient
undergo
hlaincompat
kidney
transplant
desensit
analysi
segev
colleagu
hlasensit
patient
center
undergo
desensit
kidney
transplant
live
donor
includ
differ
desensit
protocol
appli
studi
compar
patient
wait
list
receiv
deceas
donor
transplant
patient
wait
list
receiv
transplant
surviv
rate
hlasensit
recipi
percentag
point
higher
respect
also
risk
death
significantli
reduc
transplant
incompat
live
donor
desensit
treatment
import
advers
event
associ
desensit
anaphylaxi
hypotens
infect
current
aboincompat
transplant
protocol
also
includ
plasmapheresi
brynger
et
al
report
success
aboincompat
graft
without
prior
plasmapheresi
recipi
origin
felt
splenectomi
prerequisit
success
aboincompat
transplant
howev
demonstr
combin
plasmapheresi
iv
ig
without
splenectomi
allow
aboincompat
renal
transplant
plasmapheresi
aim
reduc
abo
antibodi
titer
centerspecif
critic
threshold
transplant
plasmapheresi
might
combin
rituximab
excel
outcom
report
patient
undergo
aboincompat
live
kidney
transplant
desensit
allograft
surviv
respect
plasmapheresi
also
compon
treatment
antibodymedi
allograft
reject
although
initi
report
suggest
benefici
effect
control
trial
unconvinc
nojima
et
al
report
success
treatment
antibodymedi
acut
renal
allograft
reject
combin
plasmapheresi
antibodymedi
reject
increasingli
recogn
determin
shortterm
longterm
allograft
outcom
optim
treatment
antibodymedi
reject
undetermin
moment
possibl
therapeut
approach
includ
combin
plasmapheresi
exchang
iv
ig
antibodi
remov
donorspecif
antibodi
inhibit
antibodi
product
howev
evid
safeti
efficaci
weak
optim
treatment
protocol
yet
determin
immunoabsorpt
appli
altern
plasmapheresi
found
equal
effici
method
studi
approach
highli
sensit
candid
transplant
recipi
continu
